the remaining positives, page-27

the news was a blow to PXS but not in the short term, as Garry said yesterday the next potential milestone payment from this deal was 3 years away they would not receive anything for a phase 2b trial and a phase 3 was 3 years away. So cash required by PXS in the next 3 years did not hinge on this deal. LOXL2 and Bronchitol approval should hopefully provide required cash for the short term, if either of these fail to materialise in the next 3-6 months a capital raising would definitely be on the cards but that would have been the case even if a go decision was made yesterday.